Hemostemix
Hemostemix is a publicly traded clinical-stage biotechnology company developing ACP-01 (VesCell), an autologous CD34+ stem cell therapy derived from a patient's own blood to treat ischemic conditions including PAD, CLTI, ischemic cardiomyopathy, refractory angina, and vascular dementia.
- Company typePublic
- Founded2003
- HeadquartersBlackfalds, Canada
- Headcount11–50
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Hemostemix does
Hemostemix Inc. is a clinical-stage biotechnology company headquartered in Calgary, Alberta, Canada, founded in 2003 (previously known as TheraVitae Inc.) and listed on the TSX Venture Exchange (HEM), OTCQB (HMTXF), and Frankfurt Stock Exchange (2VF0). The company develops autologous stem cell therapies for ischemic conditions that lack effective conventional treatments, with its lead product ACP-01 (marketed as VesCell) consisting of CD34+ angiogenic cell precursors isolated from a patient's own blood via peripheral venipuncture, expanded over seven days in a cGMP-compliant Montreal manufacturing facility, and administered via outpatient intramuscular injection. The platform is protected by over 90 patents across five patent families and has been evaluated across seven clinical studies involving 498 subjects, with results published in 11 peer-reviewed journals including 0% serious adverse events and 83% limb salvage in CLTI cohorts followed to 4.5 years.
The company pursues a basket IND strategy targeting six ischemic indications — peripheral arterial disease (PAD), chronic limb-threatening ischemia (CLTI), ischemic cardiomyopathy, congestive heart failure, refractory angina, and vascular dementia — all sharing microvascular perfusion insufficiency as a common mechanism. ACP-01's collection method (blood draw only) is differentiated from competitors requiring bone marrow aspiration or liposuction. The company operates a sales-led, direct-to-consumer model selling treatments at $50,000 each — well below the $300,000-$500,000 benchmarks of approved cell and gene therapies in adjacent indications. Commercial access exists in Florida under Senate Bill 1768 (Right-to-Try), The Bahamas under LARTA, and Canada through clinical frameworks, with the FDA accepting real-world evidence under IRB oversight. The company completed an FDA Pre-IND meeting in January 2026 for a basket clinical trial protocol.
Revenue mechanics rely on per-treatment cash sales plus Therapy Convertible Debentures tied to treatment revenue. Operations are funded primarily through repeated small private placements (multiple rounds in 2025-2026 totaling several million USD), insider participation by directors Mr. Lacey and Mr. Swanberg, and grant funding (e.g., $250K from McGill University Health Centre Foundation). Recent strategic moves include the appointment of Chief Commercial Officer Croom Lawrence with revenue share, a binding LOI to acquire two Dominican Republic cardiology practices in November 2025, a PreCerv Inc. spin-off housing the NCP-01 neuronal cell precursor technology, and pursuit of First Nations-led treatment center partnerships via Dr. York Hsiang.
Hemostemix firmographics
Firmographics- Name
- Hemostemix
- Legal name
- Hemostemix Inc.
- Website
- https://hemostemix.com
- Company type
- Public
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Hemostemix is a publicly traded clinical-stage biotechnology company developing ACP-01 (VesCell), an autologous CD34+ stem cell therapy derived from a patient's own blood to treat ischemic conditions including PAD, CLTI, ischemic cardiomyopathy, refractory angina, and vascular dementia.
- Ownership category
- akta.pro rank
Hemostemix industry classification
Industry- Product category
- Cell Therapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Stem Cell–Based Regenerative Therapies (HLAAAGAA)
- akta.pro secondary industry
- Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis) (HLAAAGAJ)
Keywords
Where Hemostemix is headquartered
LocationHeadquarters
- HQ city
- Blackfalds
- HQ country
- Canada
- HQ region
- North America
Offices4 records
Markets served
Hemostemix business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- ACP-01 Treatment Sales: Revenue generated from direct treatment sales at $50,000 per treatment in Florida under SB 1768, The Bahamas, and Canada. Treatment sales to no-option patients who have exhausted conventional treatments.
- Therapy Convertible Debentures: Company sold forward $1,143,983 in Therapy Convertible Debentures year-to-date, offering investors convertible debt instruments tied to treatment revenue.
- Clinical Trial Funding: Funding received from healthcare foundations (McGill University Health Centre Foundation) to support Phase II clinical trials, providing non-dilutive capital for research.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Standard ACP-01 Treatment |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels12 records
Hemostemix product offering
Product offeringCore offering
Hemostemix develops and commercializes ACP-01 (marketed as VesCell), an autologous stem cell therapy derived from a patient's own blood. CD34+ angiogenic cell precursors are isolated through peripheral venipuncture, expanded over seven days in a cGMP-compliant facility, and administered via outpatient intramuscular injection to treat ischemic conditions including peripheral arterial disease, chronic limb-threatening ischemia, refractory angina, ischemic cardiomyopathy, and vascular dementia.
Product overview
Hemostemix is a clinical-stage regenerative medicine company offering an autologous stem cell therapy platform built around ACP-01 (VesCell™), its primary product. ACP-01 is derived from a patient's own blood and evaluated for treating various ischemic and vascular conditions. The company also develops NCP-01 (Neural Cell Precursor), a complementary therapy targeting neurological applications. Both products are part of a unified platform approach where angiogenic and neural cell precursors are isolated from patient blood and processed for therapeutic use. ACP-01 has been studied across seven clinical studies involving 498 subjects, while NCP-01 represents the company's expansion into neurological indications.
Differentiator
Problem solved
Functional benefit
Products and services
- ACP-01 (VesCell) Autologous stem cell therapy derived from a patient's own blood. CD34+ angiogenic cell precursors are isolated through a standard blood draw, expanded over seven days in a cGMP-compliant facility, and administered via outpatient intramuscular injection. Evaluated in clinical research for ischemic conditions including cardiovascular ischemia, peripheral arterial disease (PAD), chronic limb threatening ischemia (CLTI), and vascular dementia.
- NCP-01 (Neural Cell Precursor) Neuronal cell precursor therapy derived from a patient's own blood, designed for potential applications in neurological conditions including vascular dementia and brain-computer interface research. Part of Hemostemix's broader cell therapy platform alongside ACP-01.
Quantifiable outcome
- 0% mortality in CLTI cohorts through 4.5 years follow-up vs 50% five-year mortality in untreated CLTI patients
- +8 more outcomes
Companies that use Hemostemix
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles4 records
Hemostemix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Hemostemix partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- Dr. Desirée CoxcorePhysician, scientist, philosopher, and bioethicist appointed to Board of Directors. Previously chaired National Stem Cell Ethics Committee in The Bahamas and spearheaded development of LARTA legislation. Founder of HEALinc global health innovation platform.
- Dr. York HsiangminorRenowned vascular surgeon and former Principal Investigator appointed as Business Consultant to advance First Nations-led healthcare partnerships. Dr. Hsiang will guide joint ventures with First Nations governments for establishing treatment centers on sovereign territories, advising on clinical staffing, physician engagement, and commercialization pathways.
- Dominican Republic Cardiology PracticesminorBinding Letter of Intent to acquire two cardiology practices in Dominican Republic as part of roll-up strategy. Physicians have treated over 200 patients with ACP-01. Acquisition aims to accelerate clinical and commercial presence and facilitate regulatory approvals.
- CytoImmune TherapeuticscoreStrategic manufacturing partnership with CytoImmune Therapeutics. $1,800,000 in financing commitments secured. BioReactor Technologies licensed for cell production.
- Dr. Nadia Giannetti, MDminorMcGill University cardiologist appointed to Scientific Advisory Board. Former Chief of Cardiology at McGill University Health Centre (2010-2021). Co-Principal Investigator of stem cell research initiative for cardiomyopathy. Leads Courtois Cardiovascular Signature Program.
- Dr. William R. ShankleminorRenowned neurologist leading Phase I clinical trial of ACP-01 for treating vascular dementia. Pre-screening up to 30 vascular dementia patients from Dr. Shankle's database.
Scale indicators15 records
Recent moves8 records
Expansion highlights6 records
Hemostemix competitors and assessment
Company assessmentDirect peers
- Mesoblast Limited: Mesoblast develops allogeneic mesenchymal stem cell therapies, including rexlemestrocel-L for chronic heart failure and inflammatory conditions. It is the most closely comparable late-stage cell therapy competitor targeting Hemostemix's cardiovascular and ischemic indications, with deeper capital but a longer path to US commercialization.
- Pluristem Therapeutics: Pluristem develops placenta-derived allogeneic cell therapy products (PLX-PAD) targeting peripheral artery disease and critical limb ischemia. It is a direct clinical-stage peer in the same ischemic/CLI cell therapy category as Hemostemix's ACP-01.
- Caladrius Biosciences: Caladrius has pursued autologous CD34+ cell therapy programs for CLI and other ischemic cardiovascular indications (including CLBS03), directly overlapping Hemostemix's autologous CD34+ angiogenic cell precursor approach for PAD/CLTI.
- Athersys (now Healios KK partner): Athersys developed MultiStem, an allogeneic cell therapy platform evaluated in ischemic and inflammatory indications including stroke and cardiovascular disease. It is a comparable clinical-stage regenerative medicine peer targeting shared mechanisms of microvascular repair.
- BrainStorm Cell Therapeutics: BrainStorm's NurOwn is an autologous cell therapy platform (MSC-derived neurotrophic factor-secreting cells) targeting neurodegenerative diseases. It overlaps with Hemostemix's NCP-01 (neuronal cell precursor) expansion into neurological indications such as vascular dementia.
Broad incumbents
- Vericel Corporation: Vericel commercializes autologous cell therapies (MACI for cartilage repair, Epicel for severe burns) and represents an established US commercial-stage cell therapy operator — a relevant incumbent comparable for Hemostemix's commercialization pathway in autologous therapies.
- Lineage Cell Therapeutics: Lineage Cell Therapeutics develops allogeneic and autologous cell transplant therapies for CNS, oncology, and ophthalmology indications. It is a broader regenerative medicine peer with overlapping platform technology and clinical-stage pipeline structure.
Emerging players
- Cynata Therapeutics: Cynata is developing iPSC-derived mesenchymal stem cell products (Cymerus platform) targeting inflammatory and vascular indications. It is an emerging player with partial overlap in ischemic disease and stem-cell-derived therapeutic approaches.
- Citius Pharmaceuticals: Citius has pursued iMSC (induced mesenchymal stem cell) therapy for CLI and other inflammatory conditions, providing another emerging stem cell competitor in the same ischemic limb disease category as Hemostemix's CLTI program.
Others
- CytoImmune Therapeutics: CytoImmune is both a manufacturing/strategic partner (BioReactor technology licensed to Hemostemix, $1.8M financing commitment) and a cell therapy peer. Comparable as a cell therapy infrastructure enabler and adjacent autologous/allogeneic developer.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Hemostemix social profiles
Digital presenceHemostemix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Hemostemix leadership team
Management profileNumber of profiles
Profiles13 records
Hemostemix funding detail
Funding detailFunding overview
Funding rounds18 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Hemostemix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Hemostemix
What does Hemostemix do?
Hemostemix develops and commercializes ACP-01 (marketed as VesCell), an autologous stem cell therapy derived from a patient's own blood. CD34+ angiogenic cell precursors are isolated through peripheral venipuncture, expanded over seven days in a cGMP-compliant facility, and administered via outpatient intramuscular injection to treat ischemic conditions including peripheral arterial disease, chronic limb-threatening ischemia, refractory angina, ischemic cardiomyopathy, and vascular dementia.
Is Hemostemix a public or private company?
Hemostemix is a public company. It is classified as public and is currently operating.
When was Hemostemix founded?
Hemostemix was founded in 2003. It employs 11 to 50 people.
Where is Hemostemix based?
Hemostemix is headquartered in Blackfalds, Canada, in the North America region.
How does Hemostemix make money?
Three revenue lines are on record. ACP-01 Treatment Sales are the primary driver. The others are therapy Convertible Debentures and clinical Trial Funding.
Who are Hemostemix's main competitors?
Direct peers on record are Mesoblast Limited, Pluristem Therapeutics, Caladrius Biosciences, Athersys (now Healios KK partner) and BrainStorm Cell Therapeutics. Broad incumbents are Vericel Corporation and Lineage Cell Therapeutics. Emerging players are Cynata Therapeutics and Citius Pharmaceuticals. CytoImmune Therapeutics is listed as an others.
Does Hemostemix have an API?
No public API is recorded for Hemostemix.
What industry is Hemostemix in?
Hemostemix's product category is Cell Therapy. Its primary akta.pro industry code is HLAAAGAA, Stem Cell–Based Regenerative Therapies, with a secondary code of HLAAAGAJ, Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis). Its NAICS code is 325414 and its SIC code is 2836.